Nω-Nitro-L-Arginine Methylester Ameliorates Myocardial Toxicity Induced by Doxorubicin

Journal of Biochemistry and Molecular Biology

Volumn 36, Issue 6, 2003, Pages 593-596

  Mansour, Mahmoud Ahmed ^a,b   El Din, Ayman Gamal ^a   Nagi, Mahmoud N ^a   Al Shabanah, Othman A ^a   Al Bekairi, Abdullah M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

CPK; Doxorubicin; L arginine; L NAME; Oxidative stress; Rat

Indexed keywords

DOXORUBICIN; LIPID PEROXIDASE; MALONALDEHYDE; N(G) NITROARGININE METHYL ESTER; ANTINEOPLASTIC ANTIBIOTIC; CREATINE KINASE; ESTER; LIPID PEROXIDE; N(G) NITROARGININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG INHIBITION; ENZYME ACTIVITY; HEART STRESS; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; TISSUE HOMOGENATE; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; HEART; HEART MUSCLE; METABOLISM; MOUSE;

ANIMALIA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CREATINE KINASE; DOXORUBICIN; ENZYME INDUCTION; ESTERS; HEART; LIPID PEROXIDES; MALE; MICE; MYOCARDIUM; NITROARGININE;

EID: 0942289825     PISSN: 12258687     EISSN: None     Source Type: Journal    
DOI: 10.5483/bmbrep.2003.36.6.593     Document Type: Article

References (32)

1. Al-Harbi, M. M., Al-Gharably, N. M., Al-Shabanah, O. A., Al-Bekairi, A. M., Osman, A. M. and Tawfik, H. N. (1992) Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother. Pharmacol. 31, 200-204.
2. Al-Shabanah, O., Mansour, M., El-Kashef, H. and Al-Bekair, A. (1998a) Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem. Mol. Biol. Int. 45, 419-427.
3. Al-Shabanah, O. A., Badary, O. A., Nagi, M. N., Al-Garably, N., Al-Rikabi, A. and Al-Bekairi, A. M. (1998b) Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J. Exp. Clin. Cancer Res. 17, 193-198.
4. Blum, R. H. and Carter, S. K. (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann. Intern. Med. 80, 249-259.
5. Buja, L. M., Ferrans, V. J., Mayer, R. J., Roberts, W. C. and Henderson, E. S. (1973) Cardiac ultrastructural changes induced by doxorubicin therapy. Cancer 32, 771-788.
6. Choi, B. M., Pae, H. O., Jang, S. I., Kim, Y. M. and Chung, H. T. (2002) Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator J. Biochem. Mol. Biol. 35, 116-126.
7. Corbett, J. A., Tilton, R. G., Chang, K., Hasan, K. S., Ido, Y., Wang, J. I., Sweetland, M. A., Lancaster, J. R., Williamson, J. R. and McDaniel, M. L. (1992) Aminoguanidine a novel inhibitor of nitric oxide formation prevents diabetic vascular dysfunction. Diabetes 41, 552-556.
8. de-Belder, A. J. and Radomski, M. W. (1994) Nitric oxide in the clinical arena. J. Hypertension 12, 617-624.
9. Doroshow, J. H., Looker, G. Y., Ifrim, I. and Myers, C. E. (1981) Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J. Clin. Invest. 68, 1053-1064.
10. Doroshow, J. H. (1983) Effect of anthracyclin antibiotics on oxygen radical formation in rat heart. Cancer Res. 43, 460-472.
11. Ellman, G. L. (1959) Tissue sulfahydryl groups. Arch. Biochem. Biophys. 82, 70-77.
12. 2+ and reversing effect of EDTA. Clin. Chem. 24, 177-184.
13. 2). Proc. Soc. Exp. Biol. Med. 158, 478-481.
14. Ishiyama, S., Hiroe, M., Nishikawa, T., Abe, S., Shimojo, T., Ito, H., Ozasa, S., Yamakawa, K., Matsuzaki, M., Mohammed, M., Nakazawa, H., Kasajima, T. and Marumo, F. (1997) Nitric oxide contributes to the progression of myocardial damages in experimental autoimmune myocarditis in rats. Circulation 95, 489-496.
15. Kaul, N., Siveski-Iiiskovic, N., Slezak, J. and Singal, P. K. (1993) Free radicals and the heart. J. Pharmacol. Toxicol. Meth. 30, 55-67.
16. Misko, T. P., Moore, W. M., Kasten, T. P., Nickols, G. A., Corbett, J. A., Tilton, R. G., McDaniel, M. L. Williamson, J. R. and Currie, M. (1993) Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmacol. 233, 119-125.
17. Morishima, I., Matsui, H., Mukawa, H., Hayashi, K., Toki, Y., Okumura, K., Ito, T. and Hayakawa, T. (2000) Melatonin a pineal hormone with antioxidant property protect against adriamycin cardiomyopathy in rats. Life Science 63, 511-521.
18. Mostafa, A. M., Nagi, M. N., Al Rikabi, A. C., Al-Shabanah, O. A. and El-Kashef, H. A. (1999) Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicin treatment in rats. Res. Commun. Mol. Pathol. Pharmacol. 106, 193-202.
19. Myers, C. (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol. 25, 10-14.
20. Myers, C. E., McGuire, W. P., Liss, R. H., Ifirm, I., Grotzinger, K. and Young, R. C. (1997) Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 19, 165-167.
21. Nagi, M. N. and Mansour, M. A. (2000) Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol. Res. 41, 283-289.
22. Nathan, C. (1992) Nitric oxide as a secretory product of mammalian cells. FASEB. J. 6, 3051-3064.
23. Ohkawa, H., Ohishi, N. and Yagi, K. (1979) Assay of lipid peroxides in normal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358.
24. Pryor, W. A. and Squadrito, G. L. (1995) The chemistry of peroxynitrite a product from reaction of nitric oxide with superoxide. Am. J. Physiol 12, 699-722.
25. Seif-el-Nasr, M. and Fahim, A. T. (2001) Antioxidant effect of N-omega-nitro-L-arginine methyl ester (L-NAME) on global cerebral ischemia in a rat model. Arzneimittelforschung 51, 628-632.
26. Singal, P. K., Deally, C. M. R. and Weinberg, L. E. (1987) Subcellular effects of adriamycin in the heart: a concise review. J. Mol. Cell Cardiol. 19, 817-828
27. Singal, P. K. and Pierce, G. N. (1986) Adriamycin stimulates low affinity calcium binding and lipid peroxidation but depresses myocardial function. Am. J. Physiol. 1250, 419-425.
28. Singal, P. K., Siveski-Iliskovic, N., Hill, M., Thomas, T. and Li, T. (1995) Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell Cardiol. 27, 1055-1063.
29. Siveski-Iliskovic, N., Kaul, N. and Singal, P. K. (1994) Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89, 2829-2835.
30. Tong, J., Ganguly, P. K. and Singal, P. K. (1991) Myocardial adrenergic changes in two stages of heart failure due to adriamycin treatment in rats. Am. J. Physiol. 620, 909-916.
31. Vivar, V. J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, K. A. and Kalyanaraman, B. (1997) Endothelial nitric oxide synthase dependent superoxide generation from adriamycin. Biochemistry 36, 11293-11297.
32. Xu, M. F., Tang, P. L., Qian, Z. M. and Ashraf, M. (2001) Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 12, 889-890.